RS50405B - Derivati kamptotecina koji imaju antitumorno dejstvo - Google Patents

Derivati kamptotecina koji imaju antitumorno dejstvo

Info

Publication number
RS50405B
RS50405B YUP-643/01A YUP64301A RS50405B RS 50405 B RS50405 B RS 50405B YU P64301 A YUP64301 A YU P64301A RS 50405 B RS50405 B RS 50405B
Authority
RS
Serbia
Prior art keywords
group
alkyl
branched
linear
aryl
Prior art date
Application number
YUP-643/01A
Other languages
English (en)
Inventor
Sergio Penco
Lucio MERLINI
Franco ZUNINO
Paolo Carminati
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.,
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.,, Istituto Nazionale Per Lo Studio E La Cura Dei Tumori, filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.,
Publication of YU64301A publication Critical patent/YU64301A/sh
Publication of RS50405B publication Critical patent/RS50405B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
YUP-643/01A 1999-03-09 2000-03-08 Derivati kamptotecina koji imaju antitumorno dejstvo RS50405B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99830124A EP1044977B1 (en) 1999-03-09 1999-03-09 Camptothecin derivatives having antitumor activity

Publications (2)

Publication Number Publication Date
YU64301A YU64301A (sh) 2005-07-19
RS50405B true RS50405B (sr) 2009-12-31

Family

ID=8243303

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-643/01A RS50405B (sr) 1999-03-09 2000-03-08 Derivati kamptotecina koji imaju antitumorno dejstvo

Country Status (39)

Country Link
US (2) US6242457B1 (sr)
EP (1) EP1044977B1 (sr)
JP (1) JP4610743B2 (sr)
KR (1) KR100702085B1 (sr)
CN (1) CN1139592C (sr)
AR (1) AR022860A1 (sr)
AT (1) ATE216998T1 (sr)
AU (1) AU774174B2 (sr)
BG (1) BG65032B1 (sr)
BR (1) BR0008840B1 (sr)
CA (1) CA2362760C (sr)
CO (1) CO5180590A1 (sr)
CZ (1) CZ304465B6 (sr)
DE (1) DE69901379T2 (sr)
DK (1) DK1044977T3 (sr)
EA (1) EA003605B1 (sr)
EE (1) EE04679B1 (sr)
EG (1) EG23999A (sr)
ES (1) ES2175919T3 (sr)
HK (1) HK1031222A1 (sr)
HR (1) HRP20010667B1 (sr)
HU (1) HU229506B1 (sr)
IL (2) IL144958A0 (sr)
IS (1) IS2003B (sr)
ME (2) MEP4008A (sr)
MX (1) MXPA01009081A (sr)
NO (1) NO328363B1 (sr)
NZ (1) NZ513393A (sr)
PE (1) PE20001485A1 (sr)
PL (1) PL222208B1 (sr)
PT (1) PT1044977E (sr)
RS (1) RS50405B (sr)
SI (1) SI1044977T1 (sr)
SK (1) SK287561B6 (sr)
TN (1) TNSN00045A1 (sr)
TR (1) TR200102603T2 (sr)
TW (1) TWI272272B (sr)
WO (1) WO2000053607A1 (sr)
ZA (1) ZA200107408B (sr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140198B1 (en) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
FR2794123B1 (fr) * 1999-05-28 2001-07-27 Aventis Pharma Sa Preparation de derives de la camptothecine et de la nothapodytine
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US20040029906A1 (en) * 2001-07-31 2004-02-12 Michael Christman Inhibitors of dna polymerase sigma
MXPA04001828A (es) * 2001-08-27 2005-03-07 Meditech Res Ltd Protocolos terapeuticos mejorados.
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
ITRM20020305A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Camptotecine con anello lattonico modificato.
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITRM20030344A1 (it) * 2003-07-14 2005-01-15 Ist Naz Stud Cura Dei Tumori 7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi.
CA2559532A1 (en) * 2004-03-26 2005-10-06 Novartis Ag Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen
CA2562904C (en) 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
ITRM20040241A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 20 con antagonisti delle integrine.
ITRM20040242A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine.
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
CN100334089C (zh) * 2004-07-21 2007-08-29 王洋 一种9－硝基喜树碱的生产方法
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
EP1827437B1 (en) * 2004-12-15 2011-11-02 Novartis AG Combinations of therapeutic agents for treating cancer
CA2590756C (en) * 2004-12-21 2014-09-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Stereoselective process and crystalline forms of a camptothecin
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
WO2007017513A2 (en) * 2005-08-10 2007-02-15 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
US8623354B2 (en) * 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2007071603A1 (en) * 2005-12-21 2007-06-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of drug-resistant tumors
EP1989212B1 (en) 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
AU2008210511A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
WO2008098701A1 (en) * 2007-02-13 2008-08-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
KR20100051837A (ko) * 2007-08-01 2010-05-18 시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이. 소아 종양의 치료
EP2096113A1 (en) 2008-02-05 2009-09-02 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. 9-substituted camptothecin derivatives as antitumor compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
US10517961B2 (en) 2015-09-25 2019-12-31 ZY Therapeutics, Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
EP0612248B1 (en) * 1991-11-15 2003-08-20 Smithkline Beecham Corporation Composition containing cisplatin and topotecan as antitumor agent.
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
GB9512670D0 (en) * 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
CN1107678C (zh) * 1996-08-19 2003-05-07 比奥纽默里克药物公司 高亲脂性喜树碱衍生物，其制备方法及其用途

Also Published As

Publication number Publication date
HU229506B1 (en) 2014-01-28
MEP4008A (xx) 2010-02-10
DE69901379T2 (de) 2002-11-07
SK287561B6 (sk) 2011-02-04
ME00017B (me) 2010-06-10
KR100702085B1 (ko) 2007-04-02
CA2362760A1 (en) 2000-09-14
CN1343209A (zh) 2002-04-03
IL144958A0 (en) 2002-06-30
IS6031A (is) 2001-07-31
ZA200107408B (en) 2002-05-29
YU64301A (sh) 2005-07-19
CZ20013077A3 (cs) 2002-01-16
NZ513393A (en) 2003-04-29
PE20001485A1 (es) 2000-12-07
TWI272272B (en) 2007-02-01
PL355094A1 (en) 2004-03-22
EG23999A (en) 2008-03-19
NO20014128D0 (no) 2001-08-24
BG105810A (en) 2002-06-28
AU774174B2 (en) 2004-06-17
EA003605B1 (ru) 2003-06-26
BR0008840A (pt) 2002-01-08
PL222208B1 (pl) 2016-07-29
BR0008840B1 (pt) 2011-12-27
TR200102603T2 (tr) 2002-01-21
CZ304465B6 (cs) 2014-05-21
AR022860A1 (es) 2002-09-04
JP2002539128A (ja) 2002-11-19
EP1044977A1 (en) 2000-10-18
ES2175919T3 (es) 2002-11-16
KR20010102519A (ko) 2001-11-15
US6589939B2 (en) 2003-07-08
CN1139592C (zh) 2004-02-25
CA2362760C (en) 2009-08-18
IL144958A (en) 2009-08-03
DE69901379D1 (de) 2002-06-06
US6242457B1 (en) 2001-06-05
HUP0200210A3 (en) 2004-03-29
AU3160400A (en) 2000-09-28
IS2003B (is) 2005-04-15
US20010008939A1 (en) 2001-07-19
DK1044977T3 (da) 2002-07-08
EE200100466A (et) 2002-12-16
CO5180590A1 (es) 2002-07-30
HRP20010667B1 (en) 2003-06-30
HK1031222A1 (en) 2001-06-08
WO2000053607A1 (en) 2000-09-14
MXPA01009081A (es) 2002-08-30
SI1044977T1 (en) 2002-08-31
SK11642001A3 (sk) 2002-01-07
HRP20010667A2 (en) 2002-08-31
TNSN00045A1 (fr) 2005-11-10
EP1044977B1 (en) 2002-05-02
BG65032B1 (bg) 2006-12-29
HUP0200210A2 (hu) 2002-05-29
JP4610743B2 (ja) 2011-01-12
EA200100954A1 (ru) 2002-04-25
EE04679B1 (et) 2006-08-15
NO20014128L (no) 2001-08-24
ATE216998T1 (de) 2002-05-15
NO328363B1 (no) 2010-02-01
PT1044977E (pt) 2002-09-30

Similar Documents

Publication Publication Date Title
RS50405B (sr) Derivati kamptotecina koji imaju antitumorno dejstvo
EA199900866A1 (ru) Пиразолопиримидиноны, которые ингибируют циклический гуанозин-3',5'-монофосфат-фосфодиэстеразу типа 5 (cgmp pde5), для лечения сексуального расстройства
NZ512731A (en) Tricyclic inhibitors of poly(ADP-ribose) polymerases
YU47099B (sh) Postupak za dobijanje makrolidnih jedinjenja
RS54776B1 (sr) Fosforoamidatni derivati 5-fluoro-2'-dezoksiuridina za upotrebu u tretmanu kancera
CO5080780A1 (es) Derivado de amida y antagonista de nociceptina
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
RS50069B (sr) Aril kondenzovana azapoliciklična jedinjenja
ES2185635T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
BR9911182A (pt) Composto, uso do mesmo, processo para o tratamento de um mamìfero, incluindo homem, de condições suscetìveis de melhora por um agonista de beta-adrenorreceptor atìpico, composição farmacêutica, e, processo para a preparação de um composto.
RS52397B (sr) Derivati pirido /2,1-a/izohinolina kao dpp-iv inhibitori
RS52562B (sr) (3-aril-piperazin-1-il) derivati 6,7-dialkoksikvinazolina, 6,7- dialkoksiftalazina i 6,7-dialkoksiizokvinolina
AR012032A1 (es) Compuestos derivados 3'-n-oxido, 3'-n-dimetilamina, 9-oxima eritromicina a y un proceso para su preparacion
HRP20010193B1 (en) Synergistic active substance combinations for controlling harmful plants
FI860111A (fi) Terapeutiska medel.
DK1204662T3 (da) Azaindoler med serotoninreceptoraffinitet
YU52992A (sh) Nezasićeni 17 beta-supstituisani 3-karboksi steroidi
RS51557B (sr) Derivati 4h-1,2,4-triazin-5-ona, njihovo dobijanje i njihova upotreba kao alfa 7 nikotinskih acetilholinskih receptora
YU49346B (sh) TRICIKLICNI 5,6-DIHIDRO-9H-PIRAZOLO [3,4-c] -1,2,4-TRIAZOLO [4,3-α] PIRIDINI
FI20001593A0 (fi) Comt-entsyymiä inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
GB2001633A (en) Anti-hypertensive 3-indolyl- tertiary butylaminopropanols
DK627088A (da) Forbindelser beslaegtet med avermectiner og milbemyciner, antiparasitiske praeparater indeholdende disse og fremgangsmaade til bekaempelse af parasitangreb
ATE281163T1 (de) Synergistiche zusammensetzungen von n- acylhomoserinlaktonen und 4-chinolinonen
YU48819B (sh) Postupak za pripremanje derivata 8-hlorohinolona
YU44592A (sh) Derivati 4-aril-3-(heteroarilkarbamido) hinolina